Scientific Poster Presentations:
Charles River was proud to support the 2019 AACR Annual Meeting. Our scientists, in collaboration with our partners, are proudly presenting 19 scientific posters. Below, you can download poster presentations covering a variety of research topics.
Sunday, March 31, 2019, 1:00 PM - 5:00 PM
- Patient-derived 3D tumor cultures for compound screening and pre-clinical drug development (Partnered with Ocello)
- PDX-derived 3D InSightTM tumor microtissues as ex-vivo human experimental models for evaluating therapeutic responses (Partnered with InSphero)
Monday, Apr 1, 8:00 a.m. - 12:00 noon
- Validation of humanized PD-1 knock-in mice as an emerging model to evaluate human specific PD-1 therapeutics
- A novel, monovalent tri-specific antibody-based molecule that simultaneously modulates PD-L1 and 4-1BB exhibits potent anti-tumoral activity in vivo (Partnered with Numab Therapeutics)
- PDX models of solid cancer express distinct cytokine profiles in humanized mice relating to their tumor infiltrating lymphocyte landscape
- Characterization of the immune checkpoint inhibitor response in the MC38 murine colon cancer model
- High content analysis of 2D and 3D oncology models for target and phenotypic drug discovery
- Validation of the interaction between a candidate compound and the intended drug target by a phenotypic rescue approach
- Bruteforcing immune oncology discovery with computational immuno-engineering (Partnered with Distributed Bio)
- Predictive models for tumor cell targeting with plinabulin, derived from in vitro screening and Affymetrix mRNA expression data (Partnered with BeyondSpring Pharmaceuticals)
Monday, Apr 1, 1:00 - 5:00 p.m.
- Translational imaging findings in a pediatric patient-derived orthotopic xenograft brain tumor model
- Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers (Partnered with 4HF Biotec GmbH)
Tuesday, Apr 2, 8:00 a.m. - 12:00 noon
- A translational immuno-oncology platform to model the tumor microenvironment in vitro
- Spatiotemporal changes in effector immunity in response to checkpoint blockade immune therapy in acute myeloid leukemia
- Broad spectrum activity of the BET inhibitor GSK 1324726A in hematologic and solid cancer cell lines in-vitro and determination of associated predictive biomarkers (Partnered with 4HF Biotec GmbH)
Wednesday, Apr 3, 8:00 a.m. - 12:00 noon
- Use of in vivo microdialysis to evaluate biomarker levels in the tumor and tumor free flank of freely-moving PDX mice
- Profile of ARX001822, a highly potent, selective and orally bioavailable A2a antagonist effective in preventing adenosinergic suppression of T cell activation (Partnered with AdoRx Therapeutics)
- Development of a vaccine model to track the CD8-specific response in large animals* (Partnered with Roche)
*Title has been changed due to its sensitive nature.
Explore Some of Our Capabilities
Cancer drug discovery has advanced significantly in the last decade. The tool kits of drug discovery scientists are becoming increasingly more sophisticated and translational. Charles River is dedicated to guiding oncology researchers, leveraging our unmatched portfolio of in vitro and in vivo models and expertise in immunology, by providing a comprehensive offering of translational oncology discovery services.